98%
921
2 minutes
20
infection has been associated with coagulopathies including hyperfibrinolysis. We compared coagulation status including thromboelastometry (ROTEM) parameters in dogs naturally infected with versus healthy dogs to determine clinicopathological parameters associated with bleeding, hypocoagulopathy, and hyperfibrinolysis. Clinical signs, white blood cell count, platelet count, hematocrit, plasmatic coagulation tests (PT, aPTT, fibrinogen concentration), D-dimer, and ROTEM S parameters (Ex-tem, In-tem, Fib-tem, Ap-tem) were analysed and compared between bleeding, nonbleeding, and control dogs and between hypo- and normocoagulable animals. Clinical signs of bleeding were present in 6/9 (67%) hypocoagulable and 1/9 (11%) normocoagulable dogs. PT, fibrinogen concentration, and several ROTEM parameters were significantly different between hypocoagulable and normocoagulabe infected dogs. Hyperfibrinolysis was identified in 44% of infected dogs and was significantly more common in bleeding and hypocoagulable dogs. Hyperfibrinolysis was significantly associated with low MCFFib-tem but not with low fibrinogen concentration or increased D-dimers. CFTEx-tem > 248 swas 100% sensitive and 89% specific to predict hyperfibrinolysis. Hyperfibrinolysis, hypocoagulability and bleeding are common in infected dogs. Only Ex-tem and Fib-tem parameters and potentially PT were associated with bleeding or hypocoagulability. Ex-tem analysis enables detection of bleeding, hypocoagulability and hyperfibrinolysis within minutes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467355 | PMC |
http://dx.doi.org/10.3390/pathogens10091077 | DOI Listing |
Acta Biomater
August 2025
Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Germany. Electronic address:
Background: Reliable in-vitro thrombogenicity testing of medical devices requires large blood volumes, which cannot be obtained from humans. Slaughterhouse blood is an ethically acceptable, cost-effective alternative. While porcine blood is already used in hemolysis testing, its use for thrombogenicity testing remains limited regarding its comparability to human blood.
View Article and Find Full Text PDFJ Thromb Haemost
August 2025
Northwell, New Hyde Park, NY, Cohen Children's Medical Center, Division of Pediatric Hematology, Oncology and Stem Cell Transplant, USA ,. Electronic address:
Introduction: Rotational Thromboelastometry (ROTEM) is a whole blood viscoelastic analyzer providing a global assessment of coagulation. Reference Intervals (RIs) for ROTEM are limited in pediatrics, often not accounting for race. Moreover, discrete RIs may be misleading.
View Article and Find Full Text PDFRes Pract Thromb Haemost
July 2025
Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Background: Low doses of recombinant activated factor (F)VII (rFVIIa), used to manage bleeding in patients with severe FXI deficiency, have been proposed to bypass effects of the FXI/FXIa inhibitor abelacimab.
Objectives: To test whether low concentrations of rFVIIa could abolish changes in coagulation parameters induced by abelacimab as measured by rotational thromboelastometry.
Methods: Whole blood specimens obtained in citrated tubes from 6 healthy donors were incubated with 15 and 30 μg/mL of abelacimab or vehicle for 10 minutes at 37 °C.
Transfusion
July 2025
Department of Emergency Medicine, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada.
Background: Rotational thromboelastometry (ROTEM) is a blood test that measures hemostatic parameters to guide hemostatic therapy. ROTEM outputs can be cognitively challenging to interpret, which may limit adherence in trauma care. Our objective was to assess hemostatic therapy administration adherence to local ROTEM recommendations.
View Article and Find Full Text PDFThromb J
July 2025
Department of Hemostasis Disorders, Medical University of Lodz, Pabianicka 62, Łódź, 93-513, Poland.
Background: Antiphospholipid antibodies (aPLs) are detected in 1-5% of the general population. They include lupus anticoagulant (LAC), anticardiolipin antibodies (aCL) and anti-β2-glycoprotein I antibodies (aβ2GPI). APL increases thrombotic risk, but the pathogenesis of this effect is not fully understood.
View Article and Find Full Text PDF